美國的非血管制支架市場 是由出版商Medtech Insight在2011年02月所出版的。
這份英文市場調查報告書包含140 Pages 價格從美金4750起跳。
非血管支架用於緩和循環路徑的一時以及慢性的閉塞、空氣與體液、以及其他全身代謝與能源交換。美國的非血管支架處置件數以每年1.5%增加、銷售量於2014年預測有1億8,920萬美元。
本報告書為美國的非血管支架市場的產品、技術概要、市場的現狀與將來預測、競爭企業與市場的機會等，概述如下。
總綱
第1章 現在以及新興的末梢血管以及非血管支架技術
第2章 非血管支架臨床的概要
第3章 非血管支架市場
- 膽管支架系統
- 胃腸管支架系統
- 肺流出路支架系統
- 尿路支架系統
第4章 企業簡介
- AbbeyMoor Medical, Inc.
- American Medical Systems, Inc.
- Boston Scientific Corporation
- Bryan Corporation
- Cook Group, Inc.
- Cordis Corporation/Johnson & Johnson
- Gyrus ACMI/Olympus Corporation
- Hood Laboratories, Inc.
- Merit Endotek/Merit Medical Systems, Inc.
附錄：企業清單
Abstract
Nonvascular stenting has been used for decades in the palliation of transient
and chronic obstructions of natural circulatory pathways that enable the
transfer of air, bodily fluids, and other substances involved in systemic
metabolic and energy exchange. These circulatory pathways include the biliary
tree as well as the gastrointestinal (GI), pulmonary, and urinary tracts. In
2010, nonvascular stenting systems were used in approximately 516,500
endoluminal recanalization procedures in the U.S., generating an estimated
$168.8 million in related sales. Over the forecast period covered by this
report, the number of nonvascular stenting procedures in the U.S. is expected
to increase at a compound annual rate of 1.5%; during the same period,
corresponding dollar sales are expected to increase at a compound annual rate
of 2.8%, reaching approximately $189.2 million in the year 2014.
This new report by Medtech Insight includes analyses of products,
technologies, current and forecast markets, competitors, and opportunities in
the U.S. nonvascular stents market. Major topics covered by this report
include a discussion of current and emerging nonvascular stenting
technologies; a clinical overview of nonvascular conditions targeted by
stenting (e.g., biliary GI, pulmonary, and urinary tract obstruction) and an
analysis of the procedure volumes and market forecasts for biliary, GI,
pulmonary, and urologic stenting systems in the U.S.
Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.
Report Statistics
- Date Published: February 2011
- Total Number of Pages: 140
- Total Number of Exhibits: 37
- Total Number of Company Profiles: 9
Table of Contents
EXECUTIVE SUMMARY
- a. Nonvascular Stenting Systems
- b. Stent Design and Materials
- c. Products and Procedures
- i. Biliary Stenting
- ii. Gastrointestinal Stenting
- iii. Pulmonary Stenting
- iv. Urologic Stenting
- v. Combined Procedure Volumes Forecast
- d. Market Analysis
- i. Biliary Stents
- ii. Gastrointestinal Stents
- iii. Pulmonary Stents
- iv. Urologic Stents
- v. Combined Market Analysis
- Exhibit ES-1: 2010, Estimated Incidence of Nonvascular Conditions Targeted
by Stenting Technologies
- Exhibit ES-2: Nonvascular Stenting, Procedure Volumes Forecast, 2009-2014
- Exhibit ES-3: Nonvascular Stenting Systems, Market Forecast, 2009-2014
1. CURRENT AND EMERGING PERIPHERAL VASCULAR AND NONVASCULAR STENTING TECHNOLOGIES
- 1.1 Stent Design
- 1.1.1 Vascular Stents
- 1.1.2 Nonvascular Stents
- 1.1.3 Stent Deployment Mechanisms
- 1.2 Stent Materials
- 1.2.1 Metal Stents
- 1.2.1.1 Absorbable Magnesium Alloys
- 1.2.1.2 Cobalt Alloys
- 1.2.1.3 Nickel-Titanium Alloys
- 1.2.1.4 Stainless Steel
- 1.2.2 Standard Polymeric Stents
- 1.2.3 Biodegradable Polymeric Stents
- 1.3 Stent Coatings
- 1.3.1 Radiopacity Enhancement
- 1.3.2 Biocompatibility Enhancement
- 1.3.3 Active Therapeutic Enhancement
- 1.3.3.1 Drug-Eluting Stents
- 1.3.3.1.1 Antirestenotic Drug-Eluting Stents
- 1.3.3.1.2 Drug Delivery Techniques
- 1.3.4 Stent Coverings and Linings
- Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent
Requirements
- Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent
Designs
- Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials
- Exhibit 1-4: Selected Polymeric Stent Materials
- Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in
Drug-Eluting Stents
- Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and
Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents
2. CLINICAL OVERVIEW OF NONVASCULAR STENTS
- 2.1 Nonvascular Conditions Targeted by Stenting
- 2.1.1 Biliary Tract Obstruction
- 2.1.1.1 Clinical Indications
- 2.1.1.2 Implantation Techniques
- 2.1.1.3 Biliary Stent Types
- 2.1.1.3.1 Plastic Devices
- 2.1.1.3.2 Metal Devices
- 2.1.1.4 Procedure Volumes
- 2.1.2 Gastrointestinal Tract Obstruction
- 2.1.2.1 Colorectal Stenting
- 2.1.2.1.1 Clinical Indications
- 2.1.2.1.2 Technology
- 2.1.2.1.3 Implantation Techniques
- 2.1.2.2 Esophageal Stenting
- 2.1.2.2.1 Technology
- 2.1.2.2.2 Implantation Techniques
- 2.1.2.3 Procedure Volumes
- 2.1.3 Pulmonary Tract Obstruction
- 2.1.3.1 Clinical Indications
- 2.1.3.2 Types of Pulmonary Stenting Systems
- 2.1.3.3 Procedure Volumes
- 2.1.4 Urinary Tract Obstruction
- 2.1.4.1 Ureteral Obstruction
- 2.1.4.1.1 Urinary Stone Disease
- 2.1.4.1.2 Ureteral Strictures
- 2.1.4.1.3 Ureteral Stenting
- 2.1.4.2 Urethral Obstruction
- 2.1.4.2.1 Benign Prostatic Hyperplasia
- 2.1.4.2.2 Urethral Strictures
- 2.1.4.2.3 Urethral Stenting
- 2.1.4.3 Procedure Volumes
- Exhibit 2-1: 2010, Biliary Obstruction, Facts and Figures
- Exhibit 2-2: Biliary Stenting, Procedure Volumes Forecast, 2009-2014
- Exhibit 2-3: 2010, Colorectal Obstruction, Facts and Figures
- Exhibit 2-4: 2010, Esophageal Obstruction, Facts and Figures
- Exhibit 2-5: Gastrointestinal Stenting, Procedure Volumes Forecast,
2009-2014
- Exhibit 2-6: 2010, Pulmonary Tract Obstruction, Facts and Figures
- Exhibit 2-7: Pulmonary Stenting, Procedure Volumes Forecast, 2009-2014
- Exhibit 2-8: 2010, Upper Urinary Tract Obstruction, Facts and Figures
- Exhibit 2-9: 2010, Lower Urinary Tract Obstruction, Facts and Figures
- Exhibit 2-10: Urologic Stenting, Procedure Volumes Forecast, 2009-2014
3. NONVASCULAR STENTS MARKET
- 3.2.1 Biliary Stenting Systems
- 3.2.1.1 Products
- 3.2.1.2 Market Forecast
- 3.2.1.3 Competitive Analysis
- 3.2.2 Gastrointestinal Stenting Systems
- 3.2.2.1 Products
- 3.2.2.2 Market Forecast
- 3.2.2.3 Competitive Analysis
- 3.2.3 Pulmonary Stenting Systems
- 3.2.3.1 Products
- 3.2.3.2 Market Forecast
- 3.2.3.3 Competitive Analysis
- 3.2.4 Urologic Stenting Systems
- 3.2.4.1 Ureteral Stenting Products
- 3.2.4.2 Urethral Stenting Products
- 3.2.4.3 Market Forecast
- 3.2.4.4 Competitive Analysis
- Exhibit 3-1: Nonvascular Stenting, Procedure Volumes Forecast, 2009-2014
- Exhibit 3-2: Nonvascular Stents, Market Forecast, 2009-2014
- Exhibit 3-3: 2011, Selected Metal and Plastic Biliary Stents
- Exhibit 3-4: Biliary Stents, Market Forecast, 2009-2014
- Exhibit 3-5: 2010, Biliary Stents Market, Share by Supplier
- Exhibit 3-6: 2011, Selected Colorectal Stents
- Exhibit 3-7: 2011, Selected Esophageal Stents
- Exhibit 3-8: Metal Gastrointestinal Stents, Market Forecast, 2009-2014
- Exhibit 3-9: 2010, Colorectal Stents Market, Share by Supplier
- Exhibit 3-10: 2010, Metal Esophageal Stents Market, Share by Supplier
- Exhibit 3-11: 2011, Selected Pulmonary Stents
- Exhibit 3-12: Pulmonary Stents, Market Forecast, 2009-2014
- Exhibit 3-13: 2010, Pulmonary Stents Market, Share by Supplier
- Exhibit 3-14: 2011, Selected Ureteral Stents
- Exhibit 3-15: 2011, Selected Prostatic Stents
- Exhibit 3-16: Urologic Stents, Market Forecast, 2009-2014
- Exhibit 3-17: 2010, Ureteral Stents Market, Share by Supplier
- Exhibit 3-18: 2010, Urethral Stents Market, Share by Supplier
4. COMPANY PROFILES
- 4.1 AbbeyMoor Medical, Inc.
- 4.2 American Medical Systems, Inc.
- 4.3 Boston Scientific Corporation
- 4.4 Bryan Corporation
- 4.5 Cook Group, Inc.
- 4.6 Cordis Corporation/Johnson & Johnson
- 4.7 Gyrus ACMI/Olympus Corporation
- 4.8 Hood Laboratories, Inc.
- 4.9 Merit Endotek/Merit Medical Systems, Inc.
APPENDIX: COMPANY LISTING
|
